Anti-COP抗体Caspase inhibitor. Acts as a regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta （IL1B） and its release during inf

产品编号 yb-13974R
英文名称 Anti-COP抗体
中文名称 Caspase抑制剂COP蛋白抗体
别    名 CAR16_HUMAN; CARD only domain-containing protein 1; CARD only protein; CARD16; Caspase recruitment domain family, member 16; Caspase recruitment domain-containing protein 16; Caspase-1 dominant-negative inhibitor pseudo-ICE; Caspase-1 inhibitor COP; COP; COP1; Pseudo interleukin-1 beta converting enzyme; Pseudo interleukin-1beta converting enzyme; PSEUDO-ICE.
 Anti-COP抗体 
说 明 书 0.1ml  0.2ml  
研究领域 细胞生物  细胞凋亡  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, Chimpanzee, Gorilla
产品应用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 23kDa
性    状 Lyophilized or Liquid
浓    度 1mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human COP1
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
 
PubMed PubMed
产品介绍 background:
Caspase inhibitor. Acts as a regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta (IL1B) and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. Also induces NF-kappa-B activation during the pro-inflammatory cytokine response. Also able to inhibit CASP1-mediated neuronal cell death, TNF-alpha, hypoxia-, UV-, and staurosporine-mediated cell death but not ER stress-mediated cell death. Acts by preventing activation of caspases CASP1 and CASP4, possibly by preventing the interaction between CASP1 and RIPK2.

Tissue Specificity:
Widely expressed. Expressed at higher level in placenta, spleen, lymph node and bone marrow. Weakly or not expressed in thymus.
 
Similarity:
Contains 1 CARD domain.